http://linked.open...gbank/description
| - MLN518 is a novel, oral, small molecule designed to inhibit type III receptor tyrosine kinases, including FLT3, (platelet-derived growth-factor receptor) PDGFR and c-KIT. Tyrosine kinases are enzymes involved in several cellular processes and are known to be activated in cancer cells to drive tumor growth. AML patients with FLT3 mutations experience earlier disease relapse and shorter survival rates compared to patients without these mutations. Approximately 25 to 30 percent of all adult AML patients have a mutation of the FLT3 gene. The use of MLN518 to treat AML has been granted fast-track status by the U.S. Food and Drug Administration. Phase I/II trials are underway. (en)
|
http://linked.open...generalReferences
| - # DeAngelo DJ, Stone RM, Heaney ML, Nimer SD, Paquette RL, Klisovic RB, Caligiuri MA, Cooper MR, Lecerf JM, Karol MD, Sheng S, Holford N, Curtin PT, Druker BJ, Heinrich MC: Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. Blood. 2006 Dec 1;108(12):3674-81. Epub 2006 Aug 10. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16902153 # Kiyoi H: [The present status of, and problems with the development of FLT3 kinase inhibitors] Rinsho Ketsueki. 2006 Apr;47(4):270-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16715961 # Kiyoi H: [Possibility of targeting FLT3 kinase for the treatment of leukemia] Rinsho Ketsueki. 2005 Mar;46(3):187-97. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16447713 # Griswold IJ, Shen LJ, La Rosee P, Demehri S, Heinrich MC, Braziel RM, McGreevey L, Haley AD, Giese N, Druker BJ, Deininger MW: Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis. Blood. 2004 Nov 1;104(9):2912-8. Epub 2004 Jul 8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15242881 # Brownlow N, Vaid M, Dibb NJ: Tandutinib inhibits FMS receptor signalling, and macrophage and osteoclast formation in vitro. Leukemia. 2008 Jan 10;. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18185521 (en)
|